{"protocolSection":{"identificationModule":{"nctId":"NCT02604342","orgStudyIdInfo":{"id":"MO29750"},"secondaryIdInfos":[{"id":"2015-000634-29","type":"EUDRACT_NUMBER"}],"organization":{"fullName":"Hoffmann-La Roche","class":"INDUSTRY"},"briefTitle":"Alectinib Versus Pemetrexed or Docetaxel in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Participants Previously Treated With Platinum-Based Chemotherapy and Crizotinib","officialTitle":"Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Pemetrexed or Docetaxel in Anaplastic Lymphoma Kinase-Positive Advanced Non Small Cell Lung Cancer Patients Previously Treated With Platinum-Based Chemotherapy and Crizotinib"},"statusModule":{"statusVerifiedDate":"2019-10","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2015-11-03","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2017-01-26","type":"ACTUAL"},"completionDateStruct":{"date":"2018-08-13","type":"ACTUAL"},"studyFirstSubmitDate":"2015-11-11","studyFirstSubmitQcDate":"2015-11-11","studyFirstPostDateStruct":{"date":"2015-11-13","type":"ESTIMATED"},"resultsFirstSubmitDate":"2018-01-24","resultsFirstSubmitQcDate":"2018-01-24","resultsFirstPostDateStruct":{"date":"2018-02-26","type":"ACTUAL"},"lastUpdateSubmitDate":"2019-10-07","lastUpdatePostDateStruct":{"date":"2019-10-29","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Hoffmann-La Roche","class":"INDUSTRY"}},"oversightModule":{"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This randomized active-controlled multicenter Phase III open-label study will evaluate and compare between treatment groups the efficacy of alectinib versus chemotherapy in participants with ALK-positive advanced NSCLC who were previously treated with chemotherapy and crizotinib, as measured by investigator-assessed progression-free survival (PFS) and to evaluate and compare between treatment groups the central nervous system (CNS) objective response rate (C-ORR) in participants with measurable CNS metastases at baseline, as assessed by an Independent Review Committee (IRC)."},"conditionsModule":{"conditions":["Non-small Cell Lung Cancer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":119,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Alectinib","type":"EXPERIMENTAL","description":"Participants will receive oral alectinib at a dose of 600 milligrams (mg) twice daily, taken with food until disease progression, unacceptable toxicity, withdrawal of consent or death.","interventionNames":["Drug: Alectinib"]},{"label":"Premetrexed/Docetaxel","type":"ACTIVE_COMPARATOR","description":"Participants will receive chemotherapy with either pemetrexed (500 milligrams per square meter \\[mg/m\\^2\\] of body surface area) or docetaxel (75 mg/m\\^2) intravenously.","interventionNames":["Drug: Docetaxel","Drug: Pemetrexed"]}],"interventions":[{"type":"DRUG","name":"Alectinib","description":"Participants will receive oral alectinib at a dose of 600 mg twice daily, taken with food until disease progression, unacceptable toxicity, withdrawal of consent or death.","armGroupLabels":["Alectinib"]},{"type":"DRUG","name":"Docetaxel","description":"Participants will receive docetaxel at a dose of 75 mg/m\\^2 of body surface area intravenously every 3 weeks, until disease progression, unacceptable toxicity, withdrawal of consent or death.","armGroupLabels":["Premetrexed/Docetaxel"],"otherNames":["Taxotere®"]},{"type":"DRUG","name":"Pemetrexed","description":"Participants will receive pemetrexed at a dose of 500 mg/m\\^2 of body surface area intravenously every 3 weeks, until disease progression, unacceptable toxicity, withdrawal of consent or death.","armGroupLabels":["Premetrexed/Docetaxel"],"otherNames":["Alimta®"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Progression-Free Survival (PFS) Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Investigator","description":"PFS was defined as the time from randomization to the first documented disease progression, as determined using RECIST v1.1, or death from any cause, whichever occurred first. As per RECIST v1.1, disease progression is a 20% increase in the sum of the diameters of target lesions, an increase in size of measurable lesions by at least 5 millimeter (mm) and the appearance of new lesions.","timeFrame":"Randomization to first documented disease progression, death from any cause, or study end (up to 33 months)"}],"secondaryOutcomes":[{"measure":"Percentage of Participants With CNS Objective Response Rate (ORR) With Measurable CNS Metastases at Baseline Using RECIST Version 1.1 as Assessed By IRC","description":"Overall response rate in subjects with confirmed CNS response (C-ORR) was defined as the percentage of subjects who attained Complete Response (CR) or Partial Response (PR) for lesions in the CNS. As per RECIST v1.1, CR: Disappearance of all target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\< 10 mm, PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters.","timeFrame":"Baseline through study end (up to 33 months)"},{"measure":"PFS Using RECIST Version 1.1 as Assessed by IRC","description":"PFS was defined as the time from randomization to the first documented disease progression, as determined using RECIST v1.1, or death from any cause, whichever occurred first. As per RECIST v1.1, disease progression is a 20% increase in the sum of the diameters of target lesions, an increase in size of measurable lesions by at least 5 mm and the appearance of new lesions.\n\nThis outcome measure was assessed as part of the primary analysis and was not repeated during final analysis.","timeFrame":"Approximately 15 months (Tumor assessments at baseline, every 6 weeks until progressive disease (PD), death or withdrawal from study prior to PD)"},{"measure":"Percentage of Participants With Objective Response of CR or PR Using RECIST Version 1.1 as Assessed by Investigator and IRC","description":"ORR was defined as the percentage of participants who attained CR or PR. As per RECIST v1.1, CR: Disappearance of all target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\< 10 mm, PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters.\n\nThe IRC assessment was part of the primary analysis and was not repeated during final analysis.","timeFrame":"Approximately 15 months (Tumor assessments at baseline, every 6 weeks until progressive disease (PD), death or withdrawal from study prior to PD)"},{"measure":"Percentage of Participants With Disease Control Using RECIST Version 1.1 as Assessed by Investigator and IRC","description":"Disease control rate (DCR) was defined as the percentage of participants who attained CR, PR, or stable disease (SD) of at least 5 weeks. As per RECIST v1.1, CR: Disappearance of all target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\< 10 mm, PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters, SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of diameters since the treatment started.\n\nThe IRC assessment was part of the primary analysis and was not repeated during final analysis.","timeFrame":"Approximately 15 months (Tumor assessments at baseline, every 6 weeks until progressive disease (PD), death or withdrawal from study prior to PD)"},{"measure":"Duration of Response (DOR) Using RECIST Version 1.1 as Assessed by Investigator and IRC","description":"DOR was defined as the time from when response (CR or PR) was first documented to first documented disease progression or death, whichever occurred first. DOR was evaluated for participants who had a best overall response (BOR) of CR or PR.\n\nThe IRC assessment was part of the primary analysis and was not repeated during final analysis.","timeFrame":"From the first documented CR or PR to the first documented disease progression, death, or study end (up to 33 months)"},{"measure":"PFS in C-ITT Population Using RECIST Version 1.1 as Assessed by Investigator and IRC","description":"PFS was defined as the time from randomization to the first documented disease progression, as determined using RECIST v1.1, or death from any cause, whichever occurred first. As per RECIST v1.1, disease progression is a 20% increase in the sum of the diameters of target lesions, an increase in size of measurable lesions by at least 5 mm and the appearance of new lesions.\n\nThis outcome measure assessment was part of the primary analysis and was not repeated during final analysis.","timeFrame":"Approximately 15 months (Tumor assessments at baseline, every 6 weeks until progressive disease (PD), death or withdrawal from study prior to PD)"},{"measure":"Time to CNS Progression in C-ITT Population Using RECIST Version 1.1 as Assessed by IRC","description":"Time to CNS progression was defined as the time from randomization until radiographic evidence of CNS progression. As per RECIST v1.1, disease progression is a 20% increase in the sum of the diameters of target lesions, an increase in size of measurable lesions by at least 5 mm and the appearance of new lesions.\n\nThis outcome measure assessment was part of the primary analysis and was not repeated during final analysis.","timeFrame":"Approximately 15 months (Tumor assessments at baseline, every 6 weeks until progressive disease (PD), death or withdrawal from study prior to PD)"},{"measure":"Percentage of Participants With Disease Control in C-ITT Population Using RECIST Version 1.1 as Assessed by IRC","description":"Disease Control Rate (DCR) was defined as the percentage of participants who attained CR, PR, or stable disease (SD) of at least 5 weeks. As per RECIST v1.1, CR: Disappearance of all target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\< 10 mm, PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters, SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of diameters since the treatment started.","timeFrame":"From first documented CR, PR, or SD lasting at least 5 weeks through study end (up to 33 months)"},{"measure":"Percentage of Participants With ORR in C-ITT Population Using RECIST Version 1.1 as Assessed by IRC","description":"ORR was defined as the percentage of participants who attained CR or PR. As per RECIST v1.1, CR: Disappearance of all target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\< 10 mm, PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters.","timeFrame":"Baseline through study end (up to 33 months)"},{"measure":"Duration of Response for Lesions in the CNS (C-DOR) Using RECIST Version 1.1 as Assessed by IRC","description":"DOR was defined as the time from when response (CR or PR) was first documented to first documented disease progression or death, whichever occurred first. C-DOR was defined in a similar way for lesions in the CNS, taking into account all lesions in the body. DOR was evaluated for participants who had a BOR of CR or PR.","timeFrame":"From the first documented CR or PR to the first documented disease progression, death, or study end (up to 33 months)"},{"measure":"Overall Survival (OS)","description":"Overall survival (OS) was defined as the time from randomization to death from any cause. OS was confounded by cross-over of participants to the alectinib arm.","timeFrame":"Randomization to death from any cause, through study end (up to 33 months)"},{"measure":"Plasma Concentration of Alectinib","timeFrame":"Predose (2 hours) at Baseline, Week 3 and Week 6"},{"measure":"Plasma Concentration of Alectinib Metabolite","timeFrame":"Predose (2 hours) at Baseline, Week 3 and Week 6"},{"measure":"Compliance of European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) Over Time","description":"Percentage of participants who filled out an EORTC QLQ-C30 questionnaire at a visit. The EORTC QLQ-C30 questionnaire consisted of 30 questions generating five functional scores (physical, role, cognitive, emotional, and social); a global health status/global quality of life scale score; three symptom scale scores (fatigue, pain, and nausea and vomiting); and six stand alone one-item scores that capture additional symptoms (dyspnea, appetite loss, sleep disturbance, constipation, and diarrhea) and perceived financial burden.","timeFrame":"Baseline through Week 138"},{"measure":"Compliance of European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer-13 (EORTC QLQ-LC13) Over Time","description":"Percentage of participants who filled out an EORTC QLQ-LC13 questionnaire at a visit. The EORTC QLQ-LC13 module generated one multiple-item scale score assessing dyspnea and a series of single item scores assessing chest pain, arm/shoulder pain, pain in other parts, coughing, sore mouth, dysphagia, peripheral neuropathy, alopecia, and hemoptysis.","timeFrame":"Baseline through Week 138"},{"measure":"Compliance of European Quality of Life (EuroQoL) 5 Dimension 5 Levels (EQ-5D-5L) Questionnaire Over Time","description":"Percentage of participants who filled out an ED-5D-5L questionnaire at a visit. EQ-5D-5L: A generic preference-based health utility measure that provides a single index value for health status. The instrument consists of two parts. The first part, health-state classification, contains five dimensions of health: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.","timeFrame":"Baseline through Week 60"},{"measure":"Time to Deterioration (TTD) in Lung Cancer Symptoms Using EORTC QLQ-LC13 Score for ITT Population","description":"TTD in the overall population is defined as time from randomization to the earliest time with a ≥10-point increase from baseline for symptoms domains (or decrease for functioning domains from baseline for cough, dyspnea \\[single item and multi-item scales\\] chest pain \\[single item\\], pain in arm/shoulder and fatigue as measured by the EORTC QLQ-LC13.","timeFrame":"Baseline through study end (up to 33 months)"},{"measure":"Time to Deterioration (TTD) in Lung Cancer Symptoms Using EORTC QLQ-LC13 Score for C-ITT Population","description":"TTD in the overall population is defined as time from randomization to the earliest time with a ≥10-point increase from baseline for symptoms domains (or decrease for functioning domains from baseline for cough, dyspnea \\[single item and multi-item scales\\] chest pain \\[single item\\], pain in arm/shoulder and fatigue as measured by the EORTC QLQ-LC13.","timeFrame":"Baseline through study end (up to 33 months)"},{"measure":"Time to Deterioration (TTD) in Lung Cancer Symptoms Using EORTC QLQ-LC30 Score for ITT Population","description":"TTD in the overall population is defined as time from randomization to the earliest time with a ≥10-point increase from baseline for symptoms domains (or decrease for functioning domains from baseline for cough, dyspnea \\[single item and multi-item scales\\] chest pain \\[single item\\], pain in arm/shoulder and fatigue as measured by the EORTC QLQ-C30.","timeFrame":"Baseline through study end (up to 33 months)"},{"measure":"Time to Deterioration (TTD) in Lung Cancer Symptoms Using EORTC QLQ-LC30 Score for C-ITT Population","description":"TTD in the overall population is defined as time from randomization to the earliest time with a ≥10-point increase from baseline for symptoms domains (or decrease for functioning domains from baseline for cough, dyspnea \\[single item and multi-item scales\\] chest pain \\[single item\\], pain in arm/shoulder and fatigue as measured by the EORTC QLQ-C30.","timeFrame":"Baseline through study end (up to 33 months)"},{"measure":"TTD in Composite of Three Symptoms (Cough, Dyspnea, and Chest Pain) Using EORTC QLQ-LC13 Score for C-ITT Population","description":"TTD for a composite of three symptoms (cough, dyspnea, chest pain) in the overall population is defined as time from randomization to the earliest time with a ≥10-point increase from baseline for any component of the composite of the three following symptoms \\[cough, dyspnea \\[multi-item subscales QLQ-LC13\\] and chest pain\\]) as measured by the EORTC QLQ-LC13.","timeFrame":"Baseline through study end (up to 33 months)"},{"measure":"TTD in Composite of Three Symptoms (Cough, Dyspnea, and Chest Pain) Using EORTC QLQ-LC13 Score for ITT Population","description":"TTD for a composite of three symptoms (cough, dyspnea, chest pain) in the overall population is defined as time from randomization to the earliest time with a ≥10-point increase from baseline for any component of the composite of the three following symptoms \\[cough, dyspnea \\[multi-item subscales QLQ-LC13\\] and chest pain\\]) as measured by the EORTC QLQ-LC13.","timeFrame":"Baseline through study end (up to 33 months)"},{"measure":"Percentage of Participants With Adverse Events (AEs)","description":"An adverse event (AE) is any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.","timeFrame":"Baseline through study end (up to 33 months)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Histologically or cytologically confirmed diagnosis of advanced or recurrent (Stage IIIB not amenable for multimodality treatment) or metastatic (Stage IV) NSCLC that is ALK-positive. ALK positivity must have been determined by a validated fluorescence in situ hybridization (FISH) test (recommended probe, Vysis ALK Break-Apart Probe) or a validated immunohistochemistry (IHC) test (recommended antibody, clone D5F3)\n* Participant had received two prior systemic lines of therapy, which must have included one line of platinum-based chemotherapy and one line of crizotinib\n* Prior CNS or leptomeningeal metastases allowed if asymptomatic\n* Participants with symptomatic CNS metastases for whom radiotherapy is not an option will be allowed to participate in this study\n* Measurable disease by RECIST Version 1.1 prior to the administration of study treatment\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2\n* For all females of childbearing potential, a negative pregnancy test must be obtained within 3 days before starting study treatment\n\nExclusion Criteria:\n\n* Participants with a previous malignancy within the past 3 years are excluded (other than curatively treated basal cell carcinoma of the skin, early gastrointestinal \\[GI\\] cancer by endoscopic resection or in situ carcinoma of the cervix)\n* Participants who have received any previous ALK inhibitor other than crizotinib\n* Any GI disorder that may affect absorption of oral medications","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Clinical Trials","affiliation":"Hoffmann-La Roche","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"GHdC Site Notre Dame","city":"Charleroi","zip":"6000","country":"Belgium","geoPoint":{"lat":50.41136,"lon":4.44448}},{"facility":"UZ Antwerpen","city":"Edegem","zip":"2650","country":"Belgium","geoPoint":{"lat":51.15662,"lon":4.44504}},{"facility":"UZ Gent","city":"Ghent","zip":"9000","country":"Belgium","geoPoint":{"lat":51.05,"lon":3.71667}},{"facility":"MBAL Serdika EOOD","city":"Sofia","zip":"1632","country":"Bulgaria","geoPoint":{"lat":42.69751,"lon":23.32415}},{"facility":"Centre Francois Baclesse","city":"Caen","zip":"14076","country":"France","geoPoint":{"lat":49.18585,"lon":-0.35912}},{"facility":"Hopital Bichat Claude Bernard ; Service de Pneumologie","city":"Paris","zip":"75877","country":"France","geoPoint":{"lat":48.85341,"lon":2.3488}},{"facility":"Hopital Du Haut Leveque; Service Des Maladies Respiratoires","city":"Pessac","zip":"33600","country":"France","geoPoint":{"lat":44.80565,"lon":-0.6324}},{"facility":"Hopital Foch; Pneumologie","city":"Suresnes","zip":"92151","country":"France","geoPoint":{"lat":48.87143,"lon":2.22929}},{"facility":"Hopital Sainte Musse; Pneumologie","city":"Toulon","zip":"83056","country":"France","geoPoint":{"lat":43.12442,"lon":5.92836}},{"facility":"Hopital Larrey; Pneumologie","city":"Toulouse","zip":"31059","country":"France","geoPoint":{"lat":43.60426,"lon":1.44367}},{"facility":"Hopital Robert Schuman; Pneumologie","city":"Vantoux","zip":"57070","country":"France","geoPoint":{"lat":49.12945,"lon":6.23201}},{"facility":"Zentralklinik Bad Berka GmbH; Abteilung Onkologie und Hämatologie","city":"Bad Berka","zip":"99437","country":"Germany","geoPoint":{"lat":50.89982,"lon":11.28245}},{"facility":"Evang. Lungenklinik Berlin Klinik für Pneumologie","city":"Berlin","zip":"13125","country":"Germany","geoPoint":{"lat":52.52437,"lon":13.41053}},{"facility":"Asklepios-Fachkliniken Muenchen-Gauting; Onkologie","city":"Gauting","zip":"82131","country":"Germany","geoPoint":{"lat":48.06919,"lon":11.37703}},{"facility":"Fachklinik für Lungenerkrankungen","city":"Immenhausen","zip":"34376","country":"Germany","geoPoint":{"lat":51.42763,"lon":9.48017}},{"facility":"Pius-Hospital; Klinik fuer Haematologie und Onkologie","city":"Oldenburg","zip":"26121","country":"Germany","geoPoint":{"lat":53.14118,"lon":8.21467}},{"facility":"Queen Elizabeth Hospital; Clinical Oncology","city":"Hong Kong","country":"Hong Kong","geoPoint":{"lat":22.27832,"lon":114.17469}},{"facility":"Queen Mary Hospital; Dept. of Clinical Oncology","city":"Hong Kong","country":"Hong Kong","geoPoint":{"lat":22.27832,"lon":114.17469}},{"facility":"Semmelweis Egyetem X; Pulmonologiai Klinika","city":"Budapest","zip":"1083","country":"Hungary","geoPoint":{"lat":47.49835,"lon":19.04045}},{"facility":"Azienda Ospedaliera di Rilievo Nazionale e di Alta Specialita San Giuseppe Moscati","city":"Avellino","state":"Campania","zip":"83100","country":"Italy","geoPoint":{"lat":40.91494,"lon":14.79103}},{"facility":"AORN Ospedali dei Colli Ospedale Monaldi; UOC Pneumologia ad indirizzo Oncologico","city":"Napoli","state":"Campania","zip":"80131","country":"Italy","geoPoint":{"lat":40.87618,"lon":14.5195}},{"facility":"Istituto Nazionale Tumori Fondazione G. Pascale; U.O.C. Oncologia Medica Toraco Polmonare","city":"Napoli","state":"Campania","zip":"80131","country":"Italy","geoPoint":{"lat":40.87618,"lon":14.5195}},{"facility":"Ospedale Provinciale Santa Maria Delle Croci; Oncologia Medica","city":"Ravenna","state":"Emilia-Romagna","zip":"48100","country":"Italy","geoPoint":{"lat":44.41344,"lon":12.20121}},{"facility":"Azienda Ospedaliera San Camillo Forlanini; U.O.C. Pneumologia Ad Indirizzo Oncologico 1","city":"Rome","state":"Lazio","zip":"00152","country":"Italy","geoPoint":{"lat":41.89193,"lon":12.51133}},{"facility":"Irccs Ospedale San Raffaele;Oncologia Medica","city":"Milan","state":"Lombardy","zip":"20132","country":"Italy","geoPoint":{"lat":45.46427,"lon":9.18951}},{"facility":"Irccs Istituto Europeo Di Oncologia (IEO); Oncologia Medica","city":"Milan","state":"Lombardy","zip":"20141","country":"Italy","geoPoint":{"lat":45.46427,"lon":9.18951}},{"facility":"POLICLINICO RODOLICO, U.O. di Oncologia Medica","city":"Catania","state":"Sicily","zip":"95100","country":"Italy","geoPoint":{"lat":37.49223,"lon":15.07041}},{"facility":"A.O. Universitaria Pisana-Ospedale Cisanello; Dipartimento Cardio Toracico-Pneumologia Ii","city":"Pisa","state":"Tuscany","zip":"56124","country":"Italy","geoPoint":{"lat":43.70853,"lon":10.4036}},{"facility":"Azienda Ospedaliera Di Perugia Ospedale s. Maria Della Misericordia; Oncologia Medica","city":"Perugia","state":"Umbria","zip":"06156","country":"Italy","geoPoint":{"lat":43.1122,"lon":12.38878}},{"facility":"Oslo Universitetssykehus HF; Radiumhospitalet","city":"Oslo","zip":"0310","country":"Norway","geoPoint":{"lat":59.91273,"lon":10.74609}},{"facility":"Medical University of Gdansk","city":"Gdansk","zip":"80-952","country":"Poland","geoPoint":{"lat":54.35227,"lon":18.64912}},{"facility":"Hospital Geral; Servico de Pneumologia","city":"Coimbra","zip":"3041-801","country":"Portugal","geoPoint":{"lat":40.20686,"lon":-8.41996}},{"facility":"IPO do Porto; Servico de Oncologia Medica","city":"Porto","zip":"4200-072","country":"Portugal","geoPoint":{"lat":41.1485,"lon":-8.61097}},{"facility":"CHVNG/E_Unidade 1; Servico de Pneumologia","city":"Vila Nova de Gaia","zip":"4434-502","country":"Portugal","geoPoint":{"lat":41.12401,"lon":-8.61241}},{"facility":"University сlinic of headaches","city":"Moscow","state":"Moscow Oblast","zip":"121467","country":"Russia"},{"facility":"FSBI\"National Medical Research Center of Oncology named after N.N.Petrov\" MHRF","city":"Saint Petersburg","state":"Sankt-Peterburg","zip":"197758","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"Main Military Clinical Hospital named after N.N. Burdenko","city":"Moscow","zip":"105229","country":"Russia","geoPoint":{"lat":55.75204,"lon":37.61781}},{"facility":"City Clinical Oncology Hospital","city":"Moscow","zip":"143423","country":"Russia","geoPoint":{"lat":55.75204,"lon":37.61781}},{"facility":"City Clinical Oncology Dispensary","city":"Saint Petersburg","zip":"197022","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"S-Pb clinical scientific practical center of specialized kinds of medical care (oncological)","city":"Saint Petersburg","zip":"197758","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"FNsP F. D. Roosevelta Banska Bystrica, II.Ocna klinika SZU","city":"Banská Bystrica","zip":"975 17","country":"Slovakia","geoPoint":{"lat":48.73947,"lon":19.14932}},{"facility":"Vychodoslovensky onkologicky ustav","city":"Košice","zip":"040 01","country":"Slovakia","geoPoint":{"lat":48.71441,"lon":21.25802}},{"facility":"Chonnam National University Hwasun Hospital","city":"Jeollanam-do","zip":"58128","country":"South Korea"},{"facility":"Korea University Guro Hospital; Oncology","city":"Seoul","zip":"152-703","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Hospital Universitario de Torrejon","city":"Torrejón de Ardoz","state":"Madrid","zip":"28850","country":"Spain","geoPoint":{"lat":40.45535,"lon":-3.46973}},{"facility":"Hospital de Cruces; Servicio de Oncologia","city":"Bilbao","state":"Vizcaya","zip":"48903","country":"Spain","geoPoint":{"lat":43.26271,"lon":-2.92528}},{"facility":"Hospital Universitario La Paz; Servicio de Oncologia","city":"Madrid","zip":"28046","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Hospital Clinico Universitario Virgen de la Victoria; Servicio de Oncologia","city":"Málaga","zip":"29010","country":"Spain","geoPoint":{"lat":36.72016,"lon":-4.42034}},{"facility":"Hospital Universitari i Politecnic La Fe de Valencia","city":"Valencia","zip":"46026","country":"Spain","geoPoint":{"lat":39.47391,"lon":-0.37966}},{"facility":"Adana Acıbadem Hospital Oncology Department","city":"Adana","zip":"01130","country":"Turkey (Türkiye)","geoPoint":{"lat":36.98615,"lon":35.32531}},{"facility":"Hacettepe Uni Medical Faculty Hospital; Oncology Dept","city":"Ankara","zip":"06100","country":"Turkey (Türkiye)","geoPoint":{"lat":39.91987,"lon":32.85427}},{"facility":"Istanbul Uni Capa Medical Faculty; Inst. of Oncology","city":"Istanbul","zip":"34093","country":"Turkey (Türkiye)","geoPoint":{"lat":41.01384,"lon":28.94966}},{"facility":"Ege University Medical Faculty; Chest Diseases","city":"Izmir","zip":"35040","country":"Turkey (Türkiye)","geoPoint":{"lat":38.41273,"lon":27.13838}},{"facility":"Inonu University Medical Faculty Turgut Ozal Medical Center Medical Oncology Department","city":"Malatya","zip":"44280","country":"Turkey (Türkiye)","geoPoint":{"lat":38.35018,"lon":38.31667}}]},"referencesModule":{"references":[{"pmid":"39661917","type":"DERIVED","citation":"Sikkema BJ, Baart SJ, Paats MS, Smit EF, Schols AMWJ, Mathijssen RHJ, van Rossum EFC, Dingemans AC. Body Weight Gain Associated With Alectinib in Patients With ALK+ Non-Small Cell Lung Cancer: Pooled Analysis of Individual Patient Data From Four Prospective Clinical Trials. J Clin Oncol. 2025 Feb 20;43(6):641-650. doi: 10.1200/JCO-24-01579. Epub 2024 Dec 11."},{"pmid":"29668860","type":"DERIVED","citation":"Novello S, Mazieres J, Oh IJ, de Castro J, Migliorino MR, Helland A, Dziadziuszko R, Griesinger F, Kotb A, Zeaiter A, Cardona A, Balas B, Johannsdottir HK, Das-Gupta A, Wolf J. Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study. Ann Oncol. 2018 Jun 1;29(6):1409-1416. doi: 10.1093/annonc/mdy121."}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"A total of 119 participants were enrolled and randomized into the study: 79 participants in the alectinib arm, and 40 participants in the chemotherapy arm.","recruitmentDetails":"The study recruited participants with Anaplastic Lymphoma Kinase (ALK)-positive advanced Non-Small Cell Lung Cancer (NSCLC) in 13 countries from November 2015 to March 2017.","groups":[{"id":"FG000","title":"Experimental: Alectinib","description":"Participants received oral alectinib at a dose of 600 milligrams (mg) twice daily, taken with food and treatment continued until disease progression, unacceptable toxicity, withdrawal of consent or death."},{"id":"FG001","title":"Active Comparator: Premetrexed/Docetaxel","description":"Participants received chemotherapy with either pemetrexed (500 milligrams per square meter \\[mg/m\\^2\\] of body surface area) or docetaxel (75 mg/m\\^2) intravenously."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"79"},{"groupId":"FG001","numSubjects":"40"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"36"},{"groupId":"FG001","numSubjects":"17"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"43"},{"groupId":"FG001","numSubjects":"23"}]}],"dropWithdraws":[{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"32"},{"groupId":"FG001","numSubjects":"16"}]},{"type":"Progression of disease","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"6"}]},{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Study Termination by Sponsor","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Intent-to-treat (ITT) population included all participants randomized in the study, irrespective of whether or not they received study drug.","groups":[{"id":"BG000","title":"Experimental: Alectinib","description":"Participants received oral alectinib at a dose of 600 milligrams (mg) twice daily, taken with food and treatment continued until disease progression, unacceptable toxicity, withdrawal of consent or death."},{"id":"BG001","title":"Active Comparator: Premetrexed/Docetaxel","description":"Participants received chemotherapy with either pemetrexed (500 milligrams per square meter \\[mg/m\\^2\\] of body surface area) or docetaxel (75 mg/m\\^2) intravenously."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"79"},{"groupId":"BG001","value":"40"},{"groupId":"BG002","value":"119"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"54.6","spread":"13.0"},{"groupId":"BG001","value":"58.8","spread":"10.5"},{"groupId":"BG002","value":"56.0","spread":"12.4"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"33"},{"groupId":"BG001","value":"20"},{"groupId":"BG002","value":"53"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"46"},{"groupId":"BG001","value":"20"},{"groupId":"BG002","value":"66"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"NUMBER","unitOfMeasure":"Participants","classes":[{"title":"Hispanic or Latino","categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"9"}]}]},{"title":"Not Hispanic or Latino","categories":[{"measurements":[{"groupId":"BG000","value":"68"},{"groupId":"BG001","value":"34"},{"groupId":"BG002","value":"102"}]}]},{"title":"Not reported","categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"5"}]}]},{"title":"Unknown","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}]}]},{"title":"Missing","categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"NUMBER","unitOfMeasure":"Participants","classes":[{"title":"White","categories":[{"measurements":[{"groupId":"BG000","value":"67"},{"groupId":"BG001","value":"32"},{"groupId":"BG002","value":"99"}]}]},{"title":"Asian","categories":[{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"14"}]}]},{"title":"Unknown","categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"5"}]}]},{"title":"Native Hawaiian or other Pacific Islander","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Progression-Free Survival (PFS) Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Investigator","description":"PFS was defined as the time from randomization to the first documented disease progression, as determined using RECIST v1.1, or death from any cause, whichever occurred first. As per RECIST v1.1, disease progression is a 20% increase in the sum of the diameters of target lesions, an increase in size of measurable lesions by at least 5 millimeter (mm) and the appearance of new lesions.","populationDescription":"ITT population included all participants randomized in the study, irrespective of whether or not they received study drug.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Randomization to first documented disease progression, death from any cause, or study end (up to 33 months)","groups":[{"id":"OG000","title":"Experimental: Alectinib","description":"Participants received oral alectinib at a dose of 600 milligrams (mg) twice daily, taken with food and treatment continued until disease progression, unacceptable toxicity, withdrawal of consent or death."},{"id":"OG001","title":"Active Comparator: Premetrexed/Docetaxel","description":"Participants received chemotherapy with either pemetrexed (500 milligrams per square meter \\[mg/m\\^2\\] of body surface area) or docetaxel (75 mg/m\\^2) intravenously."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"40"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.9","lowerLimit":"8.1","upperLimit":"15.5"},{"groupId":"OG001","value":"1.4","lowerLimit":"1.2","upperLimit":"1.6"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Stratified log-rank test","paramType":"Hazard Ratio (HR)","paramValue":"0.20","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.12","ciUpperLimit":"0.33","estimateComment":"Estimated hazard ratio obtained from stratified Cox model with treatment group as covariate."}]},{"type":"SECONDARY","title":"Percentage of Participants With CNS Objective Response Rate (ORR) With Measurable CNS Metastases at Baseline Using RECIST Version 1.1 as Assessed By IRC","description":"Overall response rate in subjects with confirmed CNS response (C-ORR) was defined as the percentage of subjects who attained Complete Response (CR) or Partial Response (PR) for lesions in the CNS. As per RECIST v1.1, CR: Disappearance of all target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\< 10 mm, PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters.","populationDescription":"ITT population with measurable CNS metastasis (mc-ITT) included all participants in ITT population with measurable CNS metastasis at baseline (as per IRC).","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Baseline through study end (up to 33 months)","groups":[{"id":"OG000","title":"Experimental: Alectinib","description":"Participants received oral alectinib at a dose of 600 milligrams (mg) twice daily, taken with food and treatment continued until disease progression, unacceptable toxicity, withdrawal of consent or death."},{"id":"OG001","title":"Active Comparator: Premetrexed/Docetaxel","description":"Participants received chemotherapy with either pemetrexed (500 milligrams per square meter \\[mg/m\\^2\\] of body surface area) or docetaxel (75 mg/m\\^2) intravenously."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"17"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66.7"},{"groupId":"OG001","value":"0.0"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"95% confidence interval of the difference (alectinib - chemotherapy) computed using Hauck-Anderson approach.","nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Chi-squared","paramType":"Difference in C-ORR","paramValue":"0.667","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.39","ciUpperLimit":"0.86"}]},{"type":"SECONDARY","title":"PFS Using RECIST Version 1.1 as Assessed by IRC","description":"PFS was defined as the time from randomization to the first documented disease progression, as determined using RECIST v1.1, or death from any cause, whichever occurred first. As per RECIST v1.1, disease progression is a 20% increase in the sum of the diameters of target lesions, an increase in size of measurable lesions by at least 5 mm and the appearance of new lesions.\n\nThis outcome measure was assessed as part of the primary analysis and was not repeated during final analysis.","populationDescription":"ITT population included all participants randomized in the study, irrespective of whether or not they received study drug.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Approximately 15 months (Tumor assessments at baseline, every 6 weeks until progressive disease (PD), death or withdrawal from study prior to PD)","groups":[{"id":"OG000","title":"Experimental: Alectinib","description":"Participants received oral alectinib at a dose of 600 milligrams (mg) twice daily, taken with food and treatment continued until disease progression, unacceptable toxicity, withdrawal of consent or death."},{"id":"OG001","title":"Active Comparator: Premetrexed/Docetaxel","description":"Participants received chemotherapy with either pemetrexed (500 milligrams per square meter \\[mg/m\\^2\\] of body surface area) or docetaxel (75 mg/m\\^2) intravenously."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"72"},{"groupId":"OG001","value":"35"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.1","lowerLimit":"6.3","upperLimit":"10.8"},{"groupId":"OG001","value":"1.6","lowerLimit":"1.3","upperLimit":"4.1"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Objective Response of CR or PR Using RECIST Version 1.1 as Assessed by Investigator and IRC","description":"ORR was defined as the percentage of participants who attained CR or PR. As per RECIST v1.1, CR: Disappearance of all target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\< 10 mm, PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters.\n\nThe IRC assessment was part of the primary analysis and was not repeated during final analysis.","populationDescription":"ITT population included all participants randomized in the study, irrespective of whether or not they received study drug.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Approximately 15 months (Tumor assessments at baseline, every 6 weeks until progressive disease (PD), death or withdrawal from study prior to PD)","groups":[{"id":"OG000","title":"Experimental: Alectinib","description":"Participants received oral alectinib at a dose of 600 milligrams (mg) twice daily, taken with food and treatment continued until disease progression, unacceptable toxicity, withdrawal of consent or death."},{"id":"OG001","title":"Active Comparator: Premetrexed/Docetaxel","description":"Participants received chemotherapy with either pemetrexed (500 milligrams per square meter \\[mg/m\\^2\\] of body surface area) or docetaxel (75 mg/m\\^2) intravenously."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"40"}]}],"classes":[{"title":"Assessed by Investigator","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"40"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"50.6"},{"groupId":"OG001","value":"2.5"}]}]},{"title":"Assessed by IRC","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"72"},{"groupId":"OG001","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"36.1"},{"groupId":"OG001","value":"11.4"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Disease Control Using RECIST Version 1.1 as Assessed by Investigator and IRC","description":"Disease control rate (DCR) was defined as the percentage of participants who attained CR, PR, or stable disease (SD) of at least 5 weeks. As per RECIST v1.1, CR: Disappearance of all target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\< 10 mm, PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters, SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of diameters since the treatment started.\n\nThe IRC assessment was part of the primary analysis and was not repeated during final analysis.","populationDescription":"ITT population included all participants randomized in the study, irrespective of whether or not they received study drug.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Approximately 15 months (Tumor assessments at baseline, every 6 weeks until progressive disease (PD), death or withdrawal from study prior to PD)","groups":[{"id":"OG000","title":"Experimental: Alectinib","description":"Participants received oral alectinib at a dose of 600 milligrams (mg) twice daily, taken with food and treatment continued until disease progression, unacceptable toxicity, withdrawal of consent or death."},{"id":"OG001","title":"Active Comparator: Premetrexed/Docetaxel","description":"Participants received chemotherapy with either pemetrexed (500 milligrams per square meter \\[mg/m\\^2\\] of body surface area) or docetaxel (75 mg/m\\^2) intravenously."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"40"}]}],"classes":[{"title":"Assessed by Investigator","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"40"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"86.1"},{"groupId":"OG001","value":"25.0"}]}]},{"title":"Assessed by IRC","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"72"},{"groupId":"OG001","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"76.4"},{"groupId":"OG001","value":"48.6"}]}]}]},{"type":"SECONDARY","title":"Duration of Response (DOR) Using RECIST Version 1.1 as Assessed by Investigator and IRC","description":"DOR was defined as the time from when response (CR or PR) was first documented to first documented disease progression or death, whichever occurred first. DOR was evaluated for participants who had a best overall response (BOR) of CR or PR.\n\nThe IRC assessment was part of the primary analysis and was not repeated during final analysis.","populationDescription":"ITT population included all participants randomized in the study, irrespective of whether or not they received study drug. Number analyzed indicates number of participants with a BOR of CR or PR.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"From the first documented CR or PR to the first documented disease progression, death, or study end (up to 33 months)","groups":[{"id":"OG000","title":"Experimental: Alectinib","description":"Participants received oral alectinib at a dose of 600 milligrams (mg) twice daily, taken with food and treatment continued until disease progression, unacceptable toxicity, withdrawal of consent or death."},{"id":"OG001","title":"Active Comparator: Premetrexed/Docetaxel","description":"Participants received chemotherapy with either pemetrexed (500 milligrams per square meter \\[mg/m\\^2\\] of body surface area) or docetaxel (75 mg/m\\^2) intravenously."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"40"}]}],"classes":[{"title":"Assessed by Investigator","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"12.0","lowerLimit":"8.3","upperLimit":"23.5"},{"groupId":"OG001","value":"2.7","lowerLimit":"NA","upperLimit":"NA","comment":"CI could not be calculated due to insufficient number of participants with the event"}]}]},{"title":"Assessed by IRC","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9.7","lowerLimit":"5.6","upperLimit":"NA","comment":"The upper CI limit could not be calculated due to an insufficient number of participants with the event"},{"groupId":"OG001","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Values could not be calculated due to an insufficient number of participants with the event"}]}]}]},{"type":"SECONDARY","title":"PFS in C-ITT Population Using RECIST Version 1.1 as Assessed by Investigator and IRC","description":"PFS was defined as the time from randomization to the first documented disease progression, as determined using RECIST v1.1, or death from any cause, whichever occurred first. As per RECIST v1.1, disease progression is a 20% increase in the sum of the diameters of target lesions, an increase in size of measurable lesions by at least 5 mm and the appearance of new lesions.\n\nThis outcome measure assessment was part of the primary analysis and was not repeated during final analysis.","populationDescription":"Intent-to-treat population with CNS metastasis (C-ITT) included participants in ITT population with CNS metastasis at baseline (as per IRC assessment).","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Approximately 15 months (Tumor assessments at baseline, every 6 weeks until progressive disease (PD), death or withdrawal from study prior to PD)","groups":[{"id":"OG000","title":"Experimental: Alectinib","description":"Participants received oral alectinib at a dose of 600 milligrams (mg) twice daily, taken with food and treatment continued until disease progression, unacceptable toxicity, withdrawal of consent or death."},{"id":"OG001","title":"Active Comparator: Premetrexed/Docetaxel","description":"Participants received chemotherapy with either pemetrexed (500 milligrams per square meter \\[mg/m\\^2\\] of body surface area) or docetaxel (75 mg/m\\^2) intravenously."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"26"}]}],"classes":[{"title":"Assessed by Investigator","categories":[{"measurements":[{"groupId":"OG000","value":"9.7","lowerLimit":"6.9","upperLimit":"NA","comment":"The upper limit of CI was not reached due to less number of participants with the event."},{"groupId":"OG001","value":"1.4","lowerLimit":"1.2","upperLimit":"1.6"}]}]},{"title":"Assessed by IRC","categories":[{"measurements":[{"groupId":"OG000","value":"8.1","lowerLimit":"6.3","upperLimit":"NA","comment":"The upper limit of CI was not reached due to less number of participants with the event."},{"groupId":"OG001","value":"1.5","lowerLimit":"1.2","upperLimit":"4.1"}]}]}]},{"type":"SECONDARY","title":"Time to CNS Progression in C-ITT Population Using RECIST Version 1.1 as Assessed by IRC","description":"Time to CNS progression was defined as the time from randomization until radiographic evidence of CNS progression. As per RECIST v1.1, disease progression is a 20% increase in the sum of the diameters of target lesions, an increase in size of measurable lesions by at least 5 mm and the appearance of new lesions.\n\nThis outcome measure assessment was part of the primary analysis and was not repeated during final analysis.","populationDescription":"C-ITT included participants in ITT population with CNS metastasis at baseline (as per IRC assessment).","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Approximately 15 months (Tumor assessments at baseline, every 6 weeks until progressive disease (PD), death or withdrawal from study prior to PD)","groups":[{"id":"OG000","title":"Experimental: Alectinib","description":"Participants received oral alectinib at a dose of 600 milligrams (mg) twice daily, taken with food and treatment continued until disease progression, unacceptable toxicity, withdrawal of consent or death."},{"id":"OG001","title":"Active Comparator: Premetrexed/Docetaxel","description":"Participants received chemotherapy with either pemetrexed (500 milligrams per square meter \\[mg/m\\^2\\] of body surface area) or docetaxel (75 mg/m\\^2) intravenously."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"26"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","lowerLimit":"6.8","upperLimit":"NA","comment":"The median and upper limit of CI was not reached due to less number of participants with the event."},{"groupId":"OG001","value":"1.6","lowerLimit":"1.3","upperLimit":"9.9"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Disease Control in C-ITT Population Using RECIST Version 1.1 as Assessed by IRC","description":"Disease Control Rate (DCR) was defined as the percentage of participants who attained CR, PR, or stable disease (SD) of at least 5 weeks. As per RECIST v1.1, CR: Disappearance of all target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\< 10 mm, PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters, SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of diameters since the treatment started.","populationDescription":"C-ITT included participants in ITT population with CNS metastasis at baseline (as per IRC assessment).","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"From first documented CR, PR, or SD lasting at least 5 weeks through study end (up to 33 months)","groups":[{"id":"OG000","title":"Experimental: Alectinib","description":"Participants received oral alectinib at a dose of 600 milligrams (mg) twice daily, taken with food and treatment continued until disease progression, unacceptable toxicity, withdrawal of consent or death."},{"id":"OG001","title":"Active Comparator: Premetrexed/Docetaxel","description":"Participants received chemotherapy with either pemetrexed (500 milligrams per square meter \\[mg/m\\^2\\] of body surface area) or docetaxel (75 mg/m\\^2) intravenously."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"52"},{"groupId":"OG001","value":"28"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"82.7"},{"groupId":"OG001","value":"25.0"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With ORR in C-ITT Population Using RECIST Version 1.1 as Assessed by IRC","description":"ORR was defined as the percentage of participants who attained CR or PR. As per RECIST v1.1, CR: Disappearance of all target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\< 10 mm, PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters.","populationDescription":"C-ITT included participants in ITT population with CNS metastasis at baseline (as per IRC assessment).","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Baseline through study end (up to 33 months)","groups":[{"id":"OG000","title":"Experimental: Alectinib","description":"Participants received oral alectinib at a dose of 600 milligrams (mg) twice daily, taken with food and treatment continued until disease progression, unacceptable toxicity, withdrawal of consent or death."},{"id":"OG001","title":"Active Comparator: Premetrexed/Docetaxel","description":"Participants received chemotherapy with either pemetrexed (500 milligrams per square meter \\[mg/m\\^2\\] of body surface area) or docetaxel (75 mg/m\\^2) intravenously."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"52"},{"groupId":"OG001","value":"28"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48.1"},{"groupId":"OG001","value":"0.0"}]}]}]},{"type":"SECONDARY","title":"Duration of Response for Lesions in the CNS (C-DOR) Using RECIST Version 1.1 as Assessed by IRC","description":"DOR was defined as the time from when response (CR or PR) was first documented to first documented disease progression or death, whichever occurred first. C-DOR was defined in a similar way for lesions in the CNS, taking into account all lesions in the body. DOR was evaluated for participants who had a BOR of CR or PR.","populationDescription":"C-ITT included participants in ITT population with CNS metastasis at baseline (as per IRC assessment). Number analyzed indicates number of participants with a BOR of CR or PR.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"From the first documented CR or PR to the first documented disease progression, death, or study end (up to 33 months)","groups":[{"id":"OG000","title":"Experimental: Alectinib","description":"Participants received oral alectinib at a dose of 600 milligrams (mg) twice daily, taken with food and treatment continued until disease progression, unacceptable toxicity, withdrawal of consent or death."},{"id":"OG001","title":"Active Comparator: Premetrexed/Docetaxel","description":"Participants received chemotherapy with either pemetrexed (500 milligrams per square meter \\[mg/m\\^2\\] of body surface area) or docetaxel (75 mg/m\\^2) intravenously."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"52"},{"groupId":"OG001","value":"28"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.9","lowerLimit":"6.2","upperLimit":"13.9"},{"groupId":"OG001","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Could not be calculated due to insufficient number of participants with the event"}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS)","description":"Overall survival (OS) was defined as the time from randomization to death from any cause. OS was confounded by cross-over of participants to the alectinib arm.","populationDescription":"ITT population included all participants randomized in the study, irrespective of whether or not they received study drug.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Randomization to death from any cause, through study end (up to 33 months)","groups":[{"id":"OG000","title":"Experimental: Alectinib","description":"Participants received oral alectinib at a dose of 600 milligrams (mg) twice daily, taken with food and treatment continued until disease progression, unacceptable toxicity, withdrawal of consent or death."},{"id":"OG001","title":"Active Comparator: Premetrexed/Docetaxel","description":"Participants received chemotherapy with either pemetrexed (500 milligrams per square meter \\[mg/m\\^2\\] of body surface area) or docetaxel (75 mg/m\\^2) intravenously."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"40"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27.8","lowerLimit":"18.2","upperLimit":"NA","comment":"The upper limit of CI was not reached due to less number of participants with the event."},{"groupId":"OG001","value":"NA","lowerLimit":"8.6","upperLimit":"NA","comment":"The median and CI was not reached due to less number of participants with the event."}]}]}]},{"type":"SECONDARY","title":"Plasma Concentration of Alectinib","populationDescription":"The Pharmacokinetic (PK) Evaluable Population included all participants who received any dose of alectinib and who had at least one post-baseline PK sample available.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"nanogram/milliliter (ng/mL)","timeFrame":"Predose (2 hours) at Baseline, Week 3 and Week 6","groups":[{"id":"OG000","title":"Experimental: Alectinib","description":"Participants received oral alectinib at a dose of 600 milligrams (mg) twice daily, taken with food and treatment continued until disease progression, unacceptable toxicity, withdrawal of consent or death."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"56"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"559","spread":"48.0"}]}]}]},{"type":"SECONDARY","title":"Plasma Concentration of Alectinib Metabolite","populationDescription":"The PK Evaluable Population included all participants who received any dose of alectinib and who had at least one post-baseline PK sample available.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"ng/mL","timeFrame":"Predose (2 hours) at Baseline, Week 3 and Week 6","groups":[{"id":"OG000","title":"Experimental: Alectinib","description":"Participants received oral alectinib at a dose of 600 milligrams (mg) twice daily, taken with food and treatment continued until disease progression, unacceptable toxicity, withdrawal of consent or death."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"56"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"240","spread":"44.8"}]}]}]},{"type":"SECONDARY","title":"Compliance of European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) Over Time","description":"Percentage of participants who filled out an EORTC QLQ-C30 questionnaire at a visit. The EORTC QLQ-C30 questionnaire consisted of 30 questions generating five functional scores (physical, role, cognitive, emotional, and social); a global health status/global quality of life scale score; three symptom scale scores (fatigue, pain, and nausea and vomiting); and six stand alone one-item scores that capture additional symptoms (dyspnea, appetite loss, sleep disturbance, constipation, and diarrhea) and perceived financial burden.","populationDescription":"ITT population included all participants randomized in the study, irrespective of whether or not they received study drug.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Baseline through Week 138","groups":[{"id":"OG000","title":"Experimental: Alectinib","description":"Participants received oral alectinib at a dose of 600 milligrams (mg) twice daily, taken with food and treatment continued until disease progression, unacceptable toxicity, withdrawal of consent or death."},{"id":"OG001","title":"Active Comparator: Premetrexed/Docetaxel","description":"Participants received chemotherapy with either pemetrexed (500 milligrams per square meter \\[mg/m\\^2\\] of body surface area) or docetaxel (75 mg/m\\^2) intravenously."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"40"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"34"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"92.4"},{"groupId":"OG001","value":"85.0"}]}]},{"title":"Treatment - Week 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"30"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"96.1"},{"groupId":"OG001","value":"83.3"}]}]},{"title":"Treatment - Week 6","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"70"},{"groupId":"OG001","value":"18"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"97.2"},{"groupId":"OG001","value":"60.0"}]}]},{"title":"Treatment - Week 12","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"95.5"},{"groupId":"OG001","value":"80.0"}]}]},{"title":"Treatment - Week 18","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"88.5"},{"groupId":"OG001","value":"50.0"}]}]},{"title":"Treatment - Week 24","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"91.1"},{"groupId":"OG001","value":"100"}]}]},{"title":"Treatment - Week 30","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"96.2"},{"groupId":"OG001","value":"66.7"}]}]},{"title":"Treatment - Week 36","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"89.8"},{"groupId":"OG001","value":"66.7"}]}]},{"title":"Treatment - Week 42","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"95.3"},{"groupId":"OG001","value":"66.7"}]}]},{"title":"Treatment - Week 48","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100"},{"groupId":"OG001","value":"100"}]}]},{"title":"Treatment - Week 54","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"97.1"},{"groupId":"OG001","value":"100"}]}]},{"title":"Treatment - Week 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100"},{"groupId":"OG001","value":"100"}]}]},{"title":"Treatment - Week 66","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"89.7"},{"groupId":"OG001","value":"100"}]}]},{"title":"Treatment - Week 72","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"88.9"},{"groupId":"OG001","value":"100"}]}]},{"title":"Treatment - Week 78","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"84.6"}]}]},{"title":"Treatment - Week 84","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"78.3"}]}]},{"title":"Treatment - Week 90","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"88.9"}]}]},{"title":"Treatment - Week 96","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"93.8"}]}]},{"title":"Treatment - Week 102","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"84.6"}]}]},{"title":"Treatment - Week 108","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100"}]}]},{"title":"Treatment - Week 114","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"83.3"}]}]},{"title":"Treatment - Week 120","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100"}]}]},{"title":"Treatment - Week 126","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100"}]}]},{"title":"Treatment - Week 132","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100"}]}]},{"title":"Treatment - Week 138","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100"}]}]}]},{"type":"SECONDARY","title":"Compliance of European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer-13 (EORTC QLQ-LC13) Over Time","description":"Percentage of participants who filled out an EORTC QLQ-LC13 questionnaire at a visit. The EORTC QLQ-LC13 module generated one multiple-item scale score assessing dyspnea and a series of single item scores assessing chest pain, arm/shoulder pain, pain in other parts, coughing, sore mouth, dysphagia, peripheral neuropathy, alopecia, and hemoptysis.","populationDescription":"ITT population included all participants randomized in the study, irrespective of whether or not they received study drug.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Baseline through Week 138","groups":[{"id":"OG000","title":"Experimental: Alectinib","description":"Participants received oral alectinib at a dose of 600 milligrams (mg) twice daily, taken with food and treatment continued until disease progression, unacceptable toxicity, withdrawal of consent or death."},{"id":"OG001","title":"Active Comparator: Premetrexed/Docetaxel","description":"Participants received chemotherapy with either pemetrexed (500 milligrams per square meter \\[mg/m\\^2\\] of body surface area) or docetaxel (75 mg/m\\^2) intravenously."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"40"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"33"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"92.4"},{"groupId":"OG001","value":"82.5"}]}]},{"title":"Treatment - Week 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"30"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"96.1"},{"groupId":"OG001","value":"83.3"}]}]},{"title":"Treatment - Week 6","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"70"},{"groupId":"OG001","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"97.2"},{"groupId":"OG001","value":"63.3"}]}]},{"title":"Treatment - Week 12","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"95.5"},{"groupId":"OG001","value":"80.0"}]}]},{"title":"Treatment - Week 18","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"88.5"},{"groupId":"OG001","value":"50.0"}]}]},{"title":"Treatment - Week 24","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"91.1"},{"groupId":"OG001","value":"100"}]}]},{"title":"Treatment - Week 30","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"96.2"},{"groupId":"OG001","value":"66.7"}]}]},{"title":"Treatment - Week 36","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"87.8"},{"groupId":"OG001","value":"66.7"}]}]},{"title":"Treatment - Week 42","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"95.3"},{"groupId":"OG001","value":"66.7"}]}]},{"title":"Treatment - Week 48","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100"},{"groupId":"OG001","value":"100"}]}]},{"title":"Treatment - Week 54","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"97.1"},{"groupId":"OG001","value":"100"}]}]},{"title":"Treatment - Week 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100"},{"groupId":"OG001","value":"100"}]}]},{"title":"Treatment - Week 66","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"89.7"},{"groupId":"OG001","value":"100"}]}]},{"title":"Treatment - Week 72","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"88.9"},{"groupId":"OG001","value":"100"}]}]},{"title":"Treatment - Week 78","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"84.6"}]}]},{"title":"Treatment - Week 84","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"78.3"}]}]},{"title":"Treatment - Week 90","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"88.9"}]}]},{"title":"Treatment - Week 96","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100"}]}]},{"title":"Treatment - Week 102","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"84.6"}]}]},{"title":"Treatment - Week 108","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100"}]}]},{"title":"Treatment - Week 114","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"83.3"}]}]},{"title":"Treatment - Week 120","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"80.0"}]}]},{"title":"Treatment - Week 126","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100"}]}]},{"title":"Treatment - Week 132","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100"}]}]},{"title":"Treatment - Week 138","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100"}]}]}]},{"type":"SECONDARY","title":"Compliance of European Quality of Life (EuroQoL) 5 Dimension 5 Levels (EQ-5D-5L) Questionnaire Over Time","description":"Percentage of participants who filled out an ED-5D-5L questionnaire at a visit. EQ-5D-5L: A generic preference-based health utility measure that provides a single index value for health status. The instrument consists of two parts. The first part, health-state classification, contains five dimensions of health: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.","populationDescription":"ITT population included all participants randomized in the study, irrespective of whether or not they received study drug.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Baseline through Week 60","groups":[{"id":"OG000","title":"Experimental: Alectinib","description":"Participants received oral alectinib at a dose of 600 milligrams (mg) twice daily, taken with food and treatment continued until disease progression, unacceptable toxicity, withdrawal of consent or death."},{"id":"OG001","title":"Active Comparator: Premetrexed/Docetaxel","description":"Participants received chemotherapy with either pemetrexed (500 milligrams per square meter \\[mg/m\\^2\\] of body surface area) or docetaxel (75 mg/m\\^2) intravenously."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"72"},{"groupId":"OG001","value":"35"}]}],"classes":[{"title":"Treatment - Week 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"72"},{"groupId":"OG001","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"88.9"},{"groupId":"OG001","value":"82.9"}]}]},{"title":"Treatment - Week 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"33"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"86.6"},{"groupId":"OG001","value":"78.8"}]}]},{"title":"Treatment - Week 6","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"62"},{"groupId":"OG001","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"91.9"},{"groupId":"OG001","value":"58.6"}]}]},{"title":"Treatment - Week 12","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"53"},{"groupId":"OG001","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"86.8"},{"groupId":"OG001","value":"80"}]}]},{"title":"Treatment - Week 18","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"72.1"},{"groupId":"OG001","value":"66.7"}]}]},{"title":"Treatment - Week 24","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"82.4"},{"groupId":"OG001","value":"100"}]}]},{"title":"Treatment - Week 30","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"80"},{"groupId":"OG001","value":"66.7"}]}]},{"title":"Treatment - Week 36","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"80"},{"groupId":"OG001","value":"50"}]}]},{"title":"Treatment - Week 42","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"91.7"},{"groupId":"OG001","value":"50"}]}]},{"title":"Treatment - Week 48","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"62.5"},{"groupId":"OG001","value":"0"}]}]},{"title":"Treatment - Week 54","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100"}]}]},{"title":"Treatment - Week 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"50"}]}]}]},{"type":"SECONDARY","title":"Time to Deterioration (TTD) in Lung Cancer Symptoms Using EORTC QLQ-LC13 Score for ITT Population","description":"TTD in the overall population is defined as time from randomization to the earliest time with a ≥10-point increase from baseline for symptoms domains (or decrease for functioning domains from baseline for cough, dyspnea \\[single item and multi-item scales\\] chest pain \\[single item\\], pain in arm/shoulder and fatigue as measured by the EORTC QLQ-LC13.","populationDescription":"ITT population included all participants randomized in the study, irrespective of whether or not they received study drug. Number analyzed indicates number of participants evaluated for specified categories.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Baseline through study end (up to 33 months)","groups":[{"id":"OG000","title":"Experimental: Alectinib","description":"Participants received oral alectinib at a dose of 600 milligrams (mg) twice daily, taken with food and treatment continued until disease progression, unacceptable toxicity, withdrawal of consent or death."},{"id":"OG001","title":"Active Comparator: Premetrexed/Docetaxel","description":"Participants received chemotherapy with either pemetrexed (500 milligrams per square meter \\[mg/m\\^2\\] of body surface area) or docetaxel (75 mg/m\\^2) intravenously."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"40"}]}],"classes":[{"title":"Coughing score","categories":[{"measurements":[{"groupId":"OG000","value":"18.1","lowerLimit":"7.2","upperLimit":"NA","comment":"The upper limit of CI was not reached due to an insufficient number of participants with the event."},{"groupId":"OG001","value":"16.6","lowerLimit":"3.3","upperLimit":"16.6"}]}]},{"title":"Dyspnoea score","categories":[{"measurements":[{"groupId":"OG000","value":"4.1","lowerLimit":"1.4","upperLimit":"11.3"},{"groupId":"OG001","value":"3.3","lowerLimit":"1.0","upperLimit":"NA","comment":"The upper limit of CI was not reached due to an insufficient number of participants with the event."}]}]},{"title":"Pain in chest score","categories":[{"measurements":[{"groupId":"OG000","value":"NA","lowerLimit":"11.1","upperLimit":"NA","comment":"The median and upper limit of CI was not reached due to less number of participants with the event."},{"groupId":"OG001","value":"NA","lowerLimit":"1.6","upperLimit":"NA","comment":"The median and upper limit of CI was not reached due to less number of participants with the event."}]}]},{"title":"Pain in arm or shoulder score","categories":[{"measurements":[{"groupId":"OG000","value":"12.5","lowerLimit":"7.4","upperLimit":"NA","comment":"The upper limit of CI was not reached due to less number of participants with the event."},{"groupId":"OG001","value":"1.9","lowerLimit":"1.6","upperLimit":"NA","comment":"The upper limit of CI was not reached due to less number of participants with the event."}]}]}]},{"type":"SECONDARY","title":"Time to Deterioration (TTD) in Lung Cancer Symptoms Using EORTC QLQ-LC13 Score for C-ITT Population","description":"TTD in the overall population is defined as time from randomization to the earliest time with a ≥10-point increase from baseline for symptoms domains (or decrease for functioning domains from baseline for cough, dyspnea \\[single item and multi-item scales\\] chest pain \\[single item\\], pain in arm/shoulder and fatigue as measured by the EORTC QLQ-LC13.","populationDescription":"C-ITT included participants in ITT population with CNS metastasis at baseline (as per IRC assessment). Number analyzed indicates number of participants evaluated for specified categories.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Baseline through study end (up to 33 months)","groups":[{"id":"OG000","title":"Experimental: Alectinib","description":"Participants received oral alectinib at a dose of 600 milligrams (mg) twice daily, taken with food and treatment continued until disease progression, unacceptable toxicity, withdrawal of consent or death."},{"id":"OG001","title":"Active Comparator: Premetrexed/Docetaxel","description":"Participants received chemotherapy with either pemetrexed (500 milligrams per square meter \\[mg/m\\^2\\] of body surface area) or docetaxel (75 mg/m\\^2) intravenously."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"52"},{"groupId":"OG001","value":"28"}]}],"classes":[{"title":"Coughing score","categories":[{"measurements":[{"groupId":"OG000","value":"NA","lowerLimit":"8.3","upperLimit":"NA","comment":"The median and upper limit of CI were not reached due to an insufficient number of participants with the event."},{"groupId":"OG001","value":"16.6","lowerLimit":"1.2","upperLimit":"16.6"}]}]},{"title":"Dyspnoea score","categories":[{"measurements":[{"groupId":"OG000","value":"9.7","lowerLimit":"1.5","upperLimit":"14.4"},{"groupId":"OG001","value":"1.4","lowerLimit":"0.8","upperLimit":"NA","comment":"The upper limit of CI was not reached due to an insufficient number of participants with the event."}]}]},{"title":"Pain in chest score","categories":[{"measurements":[{"groupId":"OG000","value":"NA","lowerLimit":"9.7","upperLimit":"NA","comment":"The upper limit of CI was not reached due to less number of participants with the event."},{"groupId":"OG001","value":"NA","lowerLimit":"1.4","upperLimit":"NA","comment":"The median and upper limit of CI was not reached due to less number of participants with the event."}]}]},{"title":"Pain in arm or shoulder score","categories":[{"measurements":[{"groupId":"OG000","value":"11.1","lowerLimit":"4.1","upperLimit":"NA","comment":"The upper limit of CI was not reached due to less number of participants with the event."},{"groupId":"OG001","value":"1.7","lowerLimit":"0.9","upperLimit":"NA","comment":"The upper limit of CI was not reached due to less number of participants with the event."}]}]}]},{"type":"SECONDARY","title":"Time to Deterioration (TTD) in Lung Cancer Symptoms Using EORTC QLQ-LC30 Score for ITT Population","description":"TTD in the overall population is defined as time from randomization to the earliest time with a ≥10-point increase from baseline for symptoms domains (or decrease for functioning domains from baseline for cough, dyspnea \\[single item and multi-item scales\\] chest pain \\[single item\\], pain in arm/shoulder and fatigue as measured by the EORTC QLQ-C30.","populationDescription":"ITT population included all participants randomized in the study, irrespective of whether or not they received study drug.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Baseline through study end (up to 33 months)","groups":[{"id":"OG000","title":"Experimental: Alectinib","description":"Participants received oral alectinib at a dose of 600 milligrams (mg) twice daily, taken with food and treatment continued until disease progression, unacceptable toxicity, withdrawal of consent or death."},{"id":"OG001","title":"Active Comparator: Premetrexed/Docetaxel","description":"Participants received chemotherapy with either pemetrexed (500 milligrams per square meter \\[mg/m\\^2\\] of body surface area) or docetaxel (75 mg/m\\^2) intravenously."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"40"}]}],"classes":[{"title":"Dyspnoea score","categories":[{"measurements":[{"groupId":"OG000","value":"13.3","lowerLimit":"2.9","upperLimit":"NA","comment":"The upper limit of CI was not reached due to an insufficient number of participants with the event."},{"groupId":"OG001","value":"8.3","lowerLimit":"1.2","upperLimit":"8.3"}]}]},{"title":"Fatigue score","categories":[{"measurements":[{"groupId":"OG000","value":"5.6","lowerLimit":"1.4","upperLimit":"NA","comment":"The upper limit of CI was not reached due to an insufficient number of participants with the event."},{"groupId":"OG001","value":"1.2","lowerLimit":"0.8","upperLimit":"NA","comment":"The upper limit of CI was not reached due to an insufficient number of participants with the event."}]}]}]},{"type":"SECONDARY","title":"Time to Deterioration (TTD) in Lung Cancer Symptoms Using EORTC QLQ-LC30 Score for C-ITT Population","description":"TTD in the overall population is defined as time from randomization to the earliest time with a ≥10-point increase from baseline for symptoms domains (or decrease for functioning domains from baseline for cough, dyspnea \\[single item and multi-item scales\\] chest pain \\[single item\\], pain in arm/shoulder and fatigue as measured by the EORTC QLQ-C30.","populationDescription":"C-ITT included participants in ITT population with CNS metastasis at baseline (as per IRC assessment).","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Baseline through study end (up to 33 months)","groups":[{"id":"OG000","title":"Experimental: Alectinib","description":"Participants received oral alectinib at a dose of 600 milligrams (mg) twice daily, taken with food and treatment continued until disease progression, unacceptable toxicity, withdrawal of consent or death."},{"id":"OG001","title":"Active Comparator: Premetrexed/Docetaxel","description":"Participants received chemotherapy with either pemetrexed (500 milligrams per square meter \\[mg/m\\^2\\] of body surface area) or docetaxel (75 mg/m\\^2) intravenously."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"52"},{"groupId":"OG001","value":"26"}]}],"classes":[{"title":"Dyspnoea score","categories":[{"measurements":[{"groupId":"OG000","value":"16.6","lowerLimit":"2.9","upperLimit":"NA","comment":"The upper limit of CI was not reached due to an insufficient number of participants with the event."},{"groupId":"OG001","value":"8.3","lowerLimit":"1.0","upperLimit":"8.3"}]}]},{"title":"Fatigue score","categories":[{"measurements":[{"groupId":"OG000","value":"14.4","lowerLimit":"2.6","upperLimit":"NA","comment":"The upper limit of CI was not reached due to less number of participants with the event."},{"groupId":"OG001","value":"1.0","lowerLimit":"0.8","upperLimit":"NA","comment":"The upper limit of CI was not reached due to less number of participants with the event."}]}]}]},{"type":"SECONDARY","title":"TTD in Composite of Three Symptoms (Cough, Dyspnea, and Chest Pain) Using EORTC QLQ-LC13 Score for C-ITT Population","description":"TTD for a composite of three symptoms (cough, dyspnea, chest pain) in the overall population is defined as time from randomization to the earliest time with a ≥10-point increase from baseline for any component of the composite of the three following symptoms \\[cough, dyspnea \\[multi-item subscales QLQ-LC13\\] and chest pain\\]) as measured by the EORTC QLQ-LC13.","populationDescription":"C-ITT included participants in ITT population with CNS metastasis at baseline (as per IRC assessment).","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Baseline through study end (up to 33 months)","groups":[{"id":"OG000","title":"Experimental: Alectinib","description":"Participants received oral alectinib at a dose of 600 milligrams (mg) twice daily, taken with food and treatment continued until disease progression, unacceptable toxicity, withdrawal of consent or death."},{"id":"OG001","title":"Active Comparator: Premetrexed/Docetaxel","description":"Participants received chemotherapy with either pemetrexed (500 milligrams per square meter \\[mg/m\\^2\\] of body surface area) or docetaxel (75 mg/m\\^2) intravenously."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"52"},{"groupId":"OG001","value":"28"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.8","lowerLimit":"0.9","upperLimit":"5.6"},{"groupId":"OG001","value":"1.4","lowerLimit":"0.8","upperLimit":"NA","comment":"The upper CT limit could not be estimated due to an insufficient number of participants with the event"}]}]}]},{"type":"SECONDARY","title":"TTD in Composite of Three Symptoms (Cough, Dyspnea, and Chest Pain) Using EORTC QLQ-LC13 Score for ITT Population","description":"TTD for a composite of three symptoms (cough, dyspnea, chest pain) in the overall population is defined as time from randomization to the earliest time with a ≥10-point increase from baseline for any component of the composite of the three following symptoms \\[cough, dyspnea \\[multi-item subscales QLQ-LC13\\] and chest pain\\]) as measured by the EORTC QLQ-LC13.","populationDescription":"ITT population included all participants randomized in the study, irrespective of whether or not they received study drug.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Baseline through study end (up to 33 months)","groups":[{"id":"OG000","title":"Experimental: Alectinib","description":"Participants received oral alectinib at a dose of 600 milligrams (mg) twice daily, taken with food and treatment continued until disease progression, unacceptable toxicity, withdrawal of consent or death."},{"id":"OG001","title":"Active Comparator: Premetrexed/Docetaxel","description":"Participants received chemotherapy with either pemetrexed (500 milligrams per square meter \\[mg/m\\^2\\] of body surface area) or docetaxel (75 mg/m\\^2) intravenously."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"40"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","lowerLimit":"0.9","upperLimit":"4.2"},{"groupId":"OG001","value":"1.4","lowerLimit":"0.9","upperLimit":"4.2"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Adverse Events (AEs)","description":"An adverse event (AE) is any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.","populationDescription":"Safety (SAF) population included all participants who received at least one dose of any study drug.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of Participants","timeFrame":"Baseline through study end (up to 33 months)","groups":[{"id":"OG000","title":"Experimental: Alectinib","description":"Participants received oral alectinib at a dose of 600 milligrams (mg) twice daily, taken with food and treatment continued until disease progression, unacceptable toxicity, withdrawal of consent or death."},{"id":"OG001","title":"Active Comparator: Premetrexed/Docetaxel","description":"Participants received chemotherapy with either pemetrexed (500 milligrams per square meter \\[mg/m\\^2\\] of body surface area) or docetaxel (75 mg/m\\^2) intravenously."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"77"},{"groupId":"OG001","value":"37"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"89.6"},{"groupId":"OG001","value":"89.2"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Approximately 15 months","description":"SAF population included all participants who received at least one dose of any study drug.","eventGroups":[{"id":"EG000","title":"Experimental: Alectinib","description":"Participants received oral alectinib at a dose of 600 milligrams (mg) twice daily, taken with food and treatment continued until disease progression, unacceptable toxicity, withdrawal of consent or death.","deathsNumAffected":26,"deathsNumAtRisk":77,"seriousNumAffected":20,"seriousNumAtRisk":77,"otherNumAffected":57,"otherNumAtRisk":77},{"id":"EG001","title":"Active Comparator: Premetrexed/Docetaxel","description":"Participants received chemotherapy with either pemetrexed (500 milligrams per square meter \\[mg/m\\^2\\] of body surface area) or docetaxel (75 mg/m\\^2) intravenously.","deathsNumAffected":4,"deathsNumAtRisk":37,"seriousNumAffected":7,"seriousNumAtRisk":37,"otherNumAffected":31,"otherNumAtRisk":37}],"seriousEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":2,"numAtRisk":37}]},{"term":"Febrile neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":2,"numAtRisk":37}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":1,"numAtRisk":37}]},{"term":"Myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":37}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":77},{"groupId":"EG001","numAffected":1,"numAtRisk":37}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":1,"numAtRisk":37}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":1,"numAtRisk":37}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":1,"numAtRisk":37}]},{"term":"Cholelithiasis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":37}]},{"term":"Abscess jaw","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":37}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":37}]},{"term":"Lung infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":1,"numAtRisk":37}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":37}]},{"term":"Pneumonia bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":1,"numAtRisk":37}]},{"term":"Ankle fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":37}]},{"term":"Jaw fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":37}]},{"term":"Skull fractured base","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":37}]},{"term":"Blood creatine phosphokinase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":37}]},{"term":"Invasive ductal breast carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":37}]},{"term":"Cerebellar ataxia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":37}]},{"term":"Epilepsy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":37}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":37}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":37}]},{"term":"Acute kidney injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":37}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":37}]},{"term":"Deep vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":37}]},{"term":"Diverticulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":37}]},{"term":"Erysipelas","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":37}]},{"term":"H1N1 Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":37}]},{"term":"Pharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":37}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":1,"numAtRisk":37}]},{"term":"Wound Complication","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":37}]},{"term":"Blood Creatinine Increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":37}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":37}]},{"term":"Death","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":37}]},{"term":"Osteoporotic fracture","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":37}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":77},{"groupId":"EG001","numAffected":4,"numAtRisk":37}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":4,"numAtRisk":37}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":16,"numAtRisk":77},{"groupId":"EG001","numAffected":4,"numAtRisk":37}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":77},{"groupId":"EG001","numAffected":2,"numAtRisk":37}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":77},{"groupId":"EG001","numAffected":6,"numAtRisk":37}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":77},{"groupId":"EG001","numAffected":2,"numAtRisk":37}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":77},{"groupId":"EG001","numAffected":6,"numAtRisk":37}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":77},{"groupId":"EG001","numAffected":9,"numAtRisk":37}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":77},{"groupId":"EG001","numAffected":2,"numAtRisk":37}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":77},{"groupId":"EG001","numAffected":3,"numAtRisk":37}]},{"term":"Blood bilirubin increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":37}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":77},{"groupId":"EG001","numAffected":4,"numAtRisk":37}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":77},{"groupId":"EG001","numAffected":2,"numAtRisk":37}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":77},{"groupId":"EG001","numAffected":4,"numAtRisk":37}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":77},{"groupId":"EG001","numAffected":2,"numAtRisk":37}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":77},{"groupId":"EG001","numAffected":2,"numAtRisk":37}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":77},{"groupId":"EG001","numAffected":3,"numAtRisk":37}]},{"term":"Neuropathy peripheral","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":77},{"groupId":"EG001","numAffected":2,"numAtRisk":37}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":77},{"groupId":"EG001","numAffected":4,"numAtRisk":37}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":37}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":77},{"groupId":"EG001","numAffected":8,"numAtRisk":37}]},{"term":"Pruritus Generalised","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":3,"numAtRisk":37}]},{"term":"Tinnitus","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":77},{"groupId":"EG001","numAffected":2,"numAtRisk":37}]},{"term":"Abdominal Pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":37}]},{"term":"Drug Hypersensitivity","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":2,"numAtRisk":37}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":77},{"groupId":"EG001","numAffected":1,"numAtRisk":37}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":77},{"groupId":"EG001","numAffected":1,"numAtRisk":37}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":37}]},{"term":"Upper Respiratory Tract Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":77},{"groupId":"EG001","numAffected":1,"numAtRisk":37}]},{"term":"Blood Creatinine Increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":37}]},{"term":"Electrocardiogram QT Prolonged","organSystem":"Investigations","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":37}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":77},{"groupId":"EG001","numAffected":3,"numAtRisk":37}]},{"term":"Musculoskeletal Chest Pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":77},{"groupId":"EG001","numAffected":2,"numAtRisk":37}]},{"term":"Paraesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":77},{"groupId":"EG001","numAffected":3,"numAtRisk":37}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights."},"pointOfContact":{"title":"Medical Communications","organization":"Hoffmann-La Roche","email":"genentech@druginfo.com","phone":"1-800-821-8590"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2017-12-01","uploadDate":"2019-08-01T17:42","filename":"Prot_002.pdf","size":1669781},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2018-08-21","uploadDate":"2019-08-01T17:54","filename":"SAP_003.pdf","size":3655249}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C582670","term":"alectinib"},{"id":"D000077143","term":"Docetaxel"},{"id":"D000068437","term":"Pemetrexed"}],"ancestors":[{"id":"D043823","term":"Taxoids"},{"id":"D043822","term":"Cyclodecanes"},{"id":"D003516","term":"Cycloparaffins"},{"id":"D006840","term":"Hydrocarbons, Alicyclic"},{"id":"D006844","term":"Hydrocarbons, Cyclic"},{"id":"D006838","term":"Hydrocarbons"},{"id":"D009930","term":"Organic Chemicals"},{"id":"D004224","term":"Diterpenes"},{"id":"D013729","term":"Terpenes"},{"id":"D006147","term":"Guanine"},{"id":"D007042","term":"Hypoxanthines"},{"id":"D011688","term":"Purinones"},{"id":"D011687","term":"Purines"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D005971","term":"Glutamates"},{"id":"D024342","term":"Amino Acids, Acidic"},{"id":"D000596","term":"Amino Acids"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D000600","term":"Amino Acids, Dicarboxylic"}]}},"hasResults":true}